Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022
- Heidelberg Pharma presents initial findings of the first in human study with ATACĀ® candidate HDP-101
- Licensing partner Magenta presents initial data from Phase I/II study with ATACĀ® candidate MGTA-117
Heidelberg Pharma AG today announced that it will present initial data from the Phase I/IIa clinical trial with HDP-101 at the 64th Annual Meeting of the American Society of Hematology (ASH). In addition, partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) will present data from its clinical trial with MGTA-117. The conference will take place from December 10 to 13, 2022 in New Orleans, USA.